We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Imfinzi sBLA for Nonsmall-Cell Lung Cancer Hits Snag in AdComm
Imfinzi sBLA for Nonsmall-Cell Lung Cancer Hits Snag in AdComm
A supplemental BLA for AstraZeneca’s blockbuster cancer drug Imfinzi (durvalumab) for treatment of nonsmall-cell lung cancer (NSCLC) hit a potential speed bump Thursday in a review by the FDA’s oncology advisory panel of the supporting clinical trial.